Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Amicus Therapeutics
(NQ:
FOLD
)
11.61
+0.31 (+2.74%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 30, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Amicus Therapeutics
< Previous
1
2
3
4
5
Next >
Amicus Therapeutics to Present at the SVB Securities Global Biopharma Conference
February 08, 2023
From
Amicus Therapeutics, Inc.
Via
GlobeNewswire
'I Think You Should Take The Money And Run': Cramer On This Stock Up 52% Over Past Month
January 25, 2023
On CNBC’s "Mad Money Lightning Round," Jim Cramer said Amicus Therapeutics Inc (NASDAQ: FOLD) is an "ideal spec.
Via
Benzinga
Amicus Therapeutics Reports Preliminary 2022 Revenue and Provides 2023 Strategic Outlook
January 09, 2023
From
Amicus Therapeutics, Inc.
Via
GlobeNewswire
Amicus Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
January 03, 2023
From
Amicus Therapeutics, Inc.
Via
GlobeNewswire
FDA Defers Action On Amicus Therapeutics' Much Awaited Pompe Disease Therapy
October 31, 2022
Via
Benzinga
Amicus Therapeutics Receives Positive CHMP Opinion for Pombiliti™ (cipaglucosidase alfa) for Late-Onset Pompe Disease
December 16, 2022
From
Amicus Therapeutics, Inc.
Via
GlobeNewswire
Amicus Therapeutics to Present at the Stifel 2022 Healthcare Conference
November 15, 2022
From
Amicus Therapeutics, Inc.
Via
GlobeNewswire
Amicus Therapeutics Provides EU Regulatory Update for AT-GAA
November 07, 2022
From
Amicus Therapeutics, Inc.
Via
GlobeNewswire
Recap: Amicus Therapeutics Q3 Earnings
November 07, 2022
Amicus Therapeutics (NASDAQ:FOLD) reported its Q3 earnings results on Monday, November 7, 2022 at 06:12 AM. Here's what investors need to know about the announcement.
Via
Benzinga
Amicus Therapeutics Announces Third Quarter 2022 Financial Results and Corporate Updates
November 07, 2022
From
Amicus Therapeutics, Inc.
Via
GlobeNewswire
Provention Bio's Second Try, Apellis's Eye Disorder Drug Review, 3 Adcom Verdicts And More: November's Key PDUFA Catalysts Biotech Investors Must Know
November 01, 2022
October proved to be a mixed month for the Food and Drug Administration’s regulatory decisions. Two new molecular entities, or NMEs, were approved during the month, bringing the tally for the...
Via
Benzinga
U.S. FDA Defers Action on Filing for AT-GAA in Late-onset Pompe Disease
October 28, 2022
From
Amicus Therapeutics, Inc.
Via
GlobeNewswire
Amicus Therapeutics to Announce Third Quarter 2022 Financial Results on November 7, 2022
October 27, 2022
From
Amicus Therapeutics, Inc.
Via
GlobeNewswire
Amicus Therapeutics Announces Participation at World Muscle Society 2022
October 11, 2022
From
Amicus Therapeutics, Inc.
Via
GlobeNewswire
AstraZeneca-Merck's Prostate Cancer Combo Drug, 3rd Try For scPharma, 3 FDA Panel Decisions And More: October's Key PDUFA Catalysts Biotech Investors Must Know
October 02, 2022
Most FDA decisions scheduled for September yielded positive results, but there were stray disappointments as well. Seven new molecular entities, or NMEs, were approved during the month, taking the...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 9, 2022
September 09, 2022
Upgrades
Via
Benzinga
Bluebird bio Seeks Back-to-Back Nods, 'Go' or 'No-Go' For Revance's Botox Rival, Amylyx' Twin Hurdles And More: September's Key PDUFA Catalysts Biotech Investors Must Know
August 31, 2022
After August’s mixed tally for Food and Drug Administration approvals, investors turn to a new month, which has a fairly loaded calendar.
Via
Benzinga
iRobot, Fox Factory, TripAdvisor And Some Other Big Gainers From Friday
August 08, 2022
U.S. stocks closed mixed on Friday following the release of jobs data for July. Here is the list of some big stocks moving higher in the previous session.
Via
Benzinga
This Healthcare Stock Is Trading Higher By 148%: Here Are 40 Stocks Moving Premarket
August 03, 2022
Gainers Helius Medical Technologies, Inc. (NASDAQ: HSDT) shares rose 159.3% to $1.67 in pre-market trading after dropping 13% on Tuesday.
Via
Benzinga
Why Quoin Pharmaceuticals Plunged Over 62%; Here Are 120 Biggest Movers From Friday
August 08, 2022
Gainers
Via
Benzinga
PayPal, SoFi Technologies And Some Other Big Stocks Moving Higher In Today's Pre-Market Session
August 03, 2022
PayPal Holdings, Inc. (NASDAQ: PYPL) rose 12% to $100.35 in pre-market trading after the company reported better-than-expected Q2 results and raised FY22 EPS guidance.
Via
Benzinga
Biotech Investors: August's Key PDUFA Catalysts You Must Know
July 31, 2022
Regulatory decisions have yet to pick up pace this year. July’s calendar was light, but the good news was that most decisions turned out to be positive. That said, none of the drugs approved during the...
Via
Benzinga
Short Volatility Alert: Amicus Therapeutics, Inc.
June 22, 2022
On Tuesday, shares of Amicus Therapeutics, Inc. (NASDAQ: FOLD) experienced volatile short activity. After the activity, the stock price went up +5.67% to $9.88. The overall...
Via
Benzinga
Attention Biotech Investors: Mark Your Calendar For These June PDUFA Dates
May 31, 2022
May turned out to be a month of mixed fortunes as far as regulatory reviews are concerned. New molecular entity approvals, an indicator of innovation in drug research, totaled three during the month,...
Via
Benzinga
The Daily Biotech Pulse: Veru Shares Up On COVID Candidate Update, FDA Approves Lilly's COVID Treatment, Latest On Sanofi-AstraZeneca RSV Vaccine
May 11, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
7 Biotech Stocks With Key Catalysts for May
May 11, 2022
The beaten-down state of biotech stocks is a major pulling point for investors who are aiming for market-leading returns.
Via
InvestorPlace
FDA Extends Review Of Amicus Therapeutics' AT-GAA For The Treatment Of Pompe Disease By Three Months
May 10, 2022
The U.S.
Via
Benzinga
Recap: Amicus Therapeutics Q1 Earnings
May 09, 2022
Amicus Therapeutics (NASDAQ:FOLD) reported its Q1 earnings results on Monday, May 9, 2022 at 07:00 AM. Here's what investors need to know about the announcement.
Via
Benzinga
Earnings Outlook For Amicus Therapeutics
May 06, 2022
Amicus Therapeutics (NASDAQ:FOLD) is set to give its latest quarterly earnings report on Monday, 2022-05-09. Here's what investors need to know before the announcement. Analysts estimate that Amicus...
Via
Benzinga
Attention Biotech Investors: Mark Your Calendar For May PDUFA Dates
May 01, 2022
The month of April was a mixed one for regulatory approvals. The Food and Drug Administration delayed approvals for at least three treatment candidates. New molecular entity, or NME, approvals, a...
Via
Benzinga
< Previous
1
2
3
4
5
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.